GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (FRA:E2Z) » Definitions » COGS-to-Revenue

Almirall (FRA:E2Z) COGS-to-Revenue : 0.36 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Almirall COGS-to-Revenue?

Almirall's Cost of Goods Sold for the three months ended in Mar. 2024 was €90.2 Mil. Its Revenue for the three months ended in Mar. 2024 was €248.8 Mil.

Almirall's COGS to Revenue for the three months ended in Mar. 2024 was 0.36.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Almirall's Gross Margin % for the three months ended in Mar. 2024 was 63.75%.


Almirall COGS-to-Revenue Historical Data

The historical data trend for Almirall's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Almirall COGS-to-Revenue Chart

Almirall Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.21 0.21 0.23 0.24

Almirall Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.35 0.11 - 0.36

Almirall COGS-to-Revenue Calculation

Almirall's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=212.479 / 894.516
=0.24

Almirall's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=90.2 / 248.8
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Almirall  (FRA:E2Z) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Almirall's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 90.2 / 248.8
=63.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Almirall COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Almirall's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Almirall (FRA:E2Z) Business Description

Traded in Other Exchanges
Address
Ronda General Mitre 151, Barcelona, ESP, 08022
Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.

Almirall (FRA:E2Z) Headlines

No Headlines